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Summary.-Twenty patients with acute myeloid leukaemia (AML) were treated
with a combination of chemotherapy which included daunorubicin, cytosine arabino-
side and 6-thioguanine (DAT). The complete remission rate was 85o% and was
achieved, in responsive cases, after an average of 2 courses of therapy. Patients
remained in hospital for an average of37*5 days during remission-induction therapy
and 3-7 days per month thereafter. The median remission period was 48 weeks and
median survival was 70 weeks. A disappointing feature was the high relapse rate.
This feature of the results re-affirms the need for a more effective form of remission
therapy.
THE treatment of AML continues to
present the most difficult challenge to
the haematological oncologist, with many
series underlining the contrast between
the success rates in AML and in acute
lymphatic leukaemia. Some recent reports,
however, have given grounds for more
optimism (Gale and Cline, 1977; Uzuka,
Liong and Yamagata, 1976; McCredie et
al., 1974). We report here the results of
treating 20 consecutive cases of AML
with a combination of cytotoxic drugs
which included daunorubicin, cytosine
arabinoside and 6-thioguanine (DAT). All
thepatients were treated atAddenbrooke's
Hospital, Cambridge.
PATIENTS AND METHODS
Treatment protocol.-The basic remission
protocol is shown in Fig. 1.
The regime combines the use of dauno-
rubicin, a cell-cycle stage-nonspecific drug,
with the 2 synergistic cell-cycle stage-
specific drugs, cytosine arabinoside and
6-thioguanine. Twelve-hourly rather than
24-hourly use of the latter combination, as
advocated by Clarkson (1972), and earlier
used at the Sloan-Kettering Institute in the
L6 protocol, appears to offer an advantage.
Our own experience with that protocol, in
which the 12-hourly combination was con-
tinued until a state of marrow hypoplasia
developed, had suggested that myelosup-
pression tended to be unduly severe, and we
therefore prefer to restrict treatment with the
DAT protocol initially to a 5-day period. In
the exceptional patient whose leukaemic-cell
population is not sharply depressed by the
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Followed by 3
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consolidation
courses.
5 7-10 5 7-10
Days
Dauno = Daunorubicin 50 mg/M2 i.v. on Day I
Ara C = Cytosine arabinoside 100 mg/M2 i.v./s.c.
12-hourly for 5 (lays
6-TG = 6-thioguanine 100 mg/M2 orally 12-hourly
for 5 days.
FIG. 1. Remission-induction protocol.
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TABLE I.-Haernatological Findings at Diagnosis (on Admission)
Case
no.
1
Sex Age
F 65
Diagnosis
AMML
2 AI 58 AML
3 Ml 59 AMML
4 F 35 AMML
5 F 65 AML
6 M1 35 AML
7 M1 57 A1IL
8 Al 27 AMML
9 F 56 Erythroleukaemia
10 Al 66 AML
11 F 39 ProMy
12 F 48 AMML
13 M 17 AML
14 F 60 AMML
15 F 37 AMML
16 F 66 AMML
17 AI 33 AMoL
18 F 36 Erythroleukaemia
19 M 45 AML
20 M 35 AMM1L
initial 5-day course, or in wuhom a rapid
rebound occurs after temporary depression,
we repeat the daunorubicin on the second
day in the next course and extend the course
from 5 days to 8. Similarly, if an unusually
severe pancytopenia develops after the initial
course, the second may be restricted to 3 or
4days,andthedoseofdaunorubicindecreased.
It is seldom necessary to vary the basic proto-
col, but we believe that a degree of flexibility
in applying ehemotherapeutie regimes plays
an important part in their success.
Maintenance therapy consisted of pulsed
courses of 1 g cyclophosphamide and 60 mg/
m2 ofCCNU at intervals of8 weeks, a modifi-
cationofthemaintenance protocolofManaster
et al. (1975).
Peripheral bloodi Mlarrow
0O blasts
Hb. WBC Blasts Platelets (±Auer
(g/dl) (109/l) (°/ ) (109/1) ro(ds)
10-2 15- 9 34 113 60
(+)
7-7 4-0 6 <10 70
6-8 72-0 19 31 30
(++)
10-0 46-2 89 120 90
9-2 2-7 68 15 60
(H-)
11-9 72-1 30 109 80
(nil)
12-9 21 8 3 119 30
(nil)
10-4 9 5 76 120 80
(nil)
8-0 13-0 25 70 50 myel
40 eryth
8-0 2-2 10 91 60
(nil)
10-2 1-8 10 98 10
(nil)
10-2 5 0 9 31 60
(+)
10-5 9-7 80 137 80
(+-++)
9-4 48 0 30 35 80
(nil)
10-0 4-8 2-5 21 45
6-8 3 -2 60 40 90
(nil)
9-4 36-0 80 22 80
(nil)
5 9 4-5 10 95 30
(+)
6-1 99-1 90 20 95
(nil)
10-8 122-0 70 30 3a
(nil)
Patients in the series. The patients treated
with the DAT regime had not previously
received anti-leukaemia therapy. They were
referred by local general practitioners and
other hospital departments in the area. In
this respect, the department acts as a primary
or secondary referal centre (Hayhoe, 1975)
and, as such, some selection ofcases may have
been made before entering our care. No
selection was made following referal. The
morphological diagnosis was made using
well-established cytochemical characteristics
(Hayhoe and Flemans, 1969). There were 7
cases of AML, 9 cases of acute myelo-
monocytic leukaemia (AMML), 2 cases of
erythroleukaemia, one acute monocytic (AMo)
and one promyelocytic (ProMy) leukaemia.
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There wN-ere 10 men and 10 wiomen wAith an
average age of 47 years (range 17-66). The
results of the haematological studies per-
formed at the time of admission are shown
in Table 1.
Suppportire care. Blood transfusions w-ere
given when the haemoglobin level fell belowN
8-0g/dl. Platelet, transfusions, wNhich wNere
freely available from the Regional Blood
Transfusion Service situated within the
hospital grounds, wNere given wrhen thrombo-
cytopenia was combined with clinical evidence
of bleeding, unless previous experience w itlh
an individual patient had led us to expect
bleeding belowN a certain platelet level.
Granulocyte transfusions from unrelated
ABO-compatible, partially HLA-compatible,
donors were given to Patients 11 and 19
during episodes of high fever (>390C) and
severe leucopenia (total WBC <0 5 x 109/1).
Granulocyte transfusions wAere not available
during the first year of the study.
The patients were treated in single rooms
whlen possible, or in 3- or 10-bed wA-ards shared
wAith other general medical patients. Access
to protected environments was not generally
available and patients w%ere allowsed to move
freely about the ward Ahen not obviously
harbouring an infection. A great deal of
attention w%as paid to dental and oral care.
Extractions or conservative t,reatment of
carious teeth were carried out as an elective
procedure wN\hen remission had been achieved.
ln the intervening period regular attention
from a dental hygienist was provided. The use
of a bacteriostatic mouth-wash and dental
brushing following each meal helped to
decrease the incidence of gingival and oral
infections. Nevertheless fungal infections
wA-ere quite common and nystatin suspension
wvith or wNithout amphotrericin-B lozenges wAere
prescribed for the treatment of oral can-
didiasis. One patient developed systemic
candidiasis.
lIESULTS
Rem1ission and suririval resldts
The criteria of a complete remission
were those followed by the M.R.C.
Working Party (1]963). The complete
remission (CR) rate was 85% in this
series. This success rate is very similar to
those recently reported from other centres
(Gale and Cline, 1977; Uzuika et al., 1976).
The average number of courses of therapy
requiired to reach a remuission was 2, and no
patient achieviing remission reqttiredl more
than 3. This feature of the response has
led us to be pessimistic over the chanices
of remission if it lecomes necessary to
begin a fourth course withotut comnplete
remission having been reached. The (Iura-
tion of remission raniged from 6 to 72
weeks, with a median value of 48 weeks.
The actuarial curve of duration of remnis-
sioIn is showni in Fig. 2. Ooie )atient
100
80 -
c
0
X 60 -
c 40
a,
20 -
0
-LX
20 40 60 80
IV E E K S
100L 12
100 120
Fii(c. 2.- -Actuarial curv'x-e of (luirationt of first
remission (it 17). M.ean (Iturationi of
remission 48 w7eeks. O - Continuing i-
missioll; Relapse. t ifldicates patient
(I'niig reIlisSo101).
(Patient 18) achieved onlv partial remis-
sion with this treatment, butt continued
to complete remission following an altered
induction regime. Two patients failed to
res)on(d sufficienitly! to enter either CR
or- PR grouLps ancd are shown as NR (no
remnissioni) in Table II. The average period
of time required to achieve remission was
33 days, which is very similar to the
average interval betxween the start of
treatment anx(l remissioni observecl by
(Gale and Cline (1977).
The median d(uratioin of survival for all
patients was 70 weeks. The actuarial
cuirve of survival is shown in Fig. 3.
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No. of
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2
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3
2
2
NR
2
2
2
2
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2
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1
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Fie- . 3.-Actuarial curve of survival (I1 = 20).
Mean survival = 70 weeks. 0 = Suirvivors;
* --Deaths.
Quality of sarvival
The quality of survival in patients with
leukaemia is an important factor when
considering the efficacy of a treatment
regime, and has received a great deal of
attention recently (Burge et al., 1975).
The average number of days each patient
spent in hospital for remission induction
therapy was 37*5 days; for those who
entered remission this figure was 31 days.
Following this period the average number
of days per month in hospital for 17
patients in whom this can be assessed
was 3-7 days per month. This included all
remission consolidation therapy for
patients living sufficiently far away for
twice-daily visits to the hospital to be
impractical, or for whom no satisfactory
arrangements could be made for their
injections to be given by a general practi-
tioner or district nurse. Intercurrent
infections requiring admission care, and
further re-induction courses following
relapse or terminal care, also contribute
to the average of 3 7 days per month.
Fifteen of the 20 patients returned to
full occupational or home activities, and
when assessed for range of activity would
satisfy Grade 5 quality-of-life scale of
Burge et al. (1975), in whose series the
TABLE II. Number
Case
no.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
1'9
20
NR-
PR =
100 h-
I I3
0--o
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period in hospital for remission induction
was 36 days, and later inpatient visits
averaged 3-4 days per month. Their
non-aggressive treatment regime produced
a median survival of 34 weeks compared
with 70 weeks in our group; there is
therefore a clear advantage to be gained
from the use of the more intensive regime
which does not merely result in an attenu-
ated life but holds out a real possibility
of a prolonged enjoyable existence.
Progress following therapy
The details of progress of each patient
following the start oftreatment are shown
in Table II. Bone marrow aspirations were
performed one day before the start of a
course of therapy if there was any doubt
from the evidence of the peripheral blood
count that the marrow cellularity had
recovered sufficiently well from the pre-
vious course to justify further treatment
at that stage. Thereafter bone marrow
asspirations were performed at intervals
of 2 months.
Induction of second remtission following
relapse
Seven patients have relapsed while
receiving maintenance therapy. Three
patients (Nos. 2, 6 and 8) achieved pro-
longed second remissions aiid returned to
work following the re-induction therapy.
The number of courses for reinduction
of remission in this small group was 2, 1
and 2 respectively. These were obtained
after an average of 28 days from the diag-
nosis of relapse. Four patients failed to
gain a second remission (Nos. 4, 5, 13
and 17).
Causes of death
Eight patients have died during the
course of this study, but there was only
one early death (less than 6 weeks after
diagnosis). All were in relapse at the
time of death, apart from Patient No. 3
who died at home in remission with pneu-
monia which was presumed to be viral.
The causes of death in the remaining 7
patients were infection in 6 (3 Gram-
negative septicaemia, one systemic candi-
diasis, 2 staphylococcal septicaemia and
one with an unidentified organism). One
patient died of a cerebellar haemorrhage.
All patients were severely neutropenic
(neutrophil count <500/cm3) at the time
of death, and all had severe thrombo-
cytopenia. No granulocyte transfusions
were given to these patients, because no
facilities for such provision were available
during the early part of the study. In
our experience, haemorrhage is an uncom-
mon cause of death, and in Patient 13
cerebellar haemorrhage occurred at a time
of hectic fever. Others have reported
similarly low incidence of haemorrhage
as a terminal event (Smith, Powles and
McElwain, 1976).
Prognostic featwres
The value of clinical feattures and results
of laboratory studies in forecasting the
outcome in an individual case ofleukaemia
has recently been reviewed by Gehan et al.
(1976). Galton, Howard and Pike (1975)
have drawn attention to the decreased
survival with advancing age and the
unfavourable effect ofa low platelet count.
These features were not associated with
poorer results in our series. The presence
or absence of Auer rods in AML has
conflicting prognostic value (Ellison et al.,
1975; Henderson et al., 1975). In our series
Auer rods were found in 9 cases (450o)
which is very similar to the percentage
quoted at Roswell Park (Henderson et al.,
1975) but we could not confirm the poor
prognostic outlook of the Auer-rod-nega-
tive group. The total WBC at the time of
presentation varied between 1.8 and
122-0 x 109/1, withno apparent advantage
to those at either end of the range,
although Patient 18, in whom a diagnosis
of erythroleukaemia was made following
a routine blood count, entered only a
partial remission on this protocol and
finally reached a state of complete remis-
sion with adriamycin, vincristine and
asparaginase. Itremains to be seenwhetherTHE TREATMENT OF ACUTE MYELOID LEUKAEMIA WITH DAT
any features which may hold prognostic
value will emerge as the study progresses.
DISCUSSION
The treatment protocol which has been
described has produced a remission rate
of 85% in previously untreated patients
with AML of all age groups. With a rela-
tively small series it is difficult to draw
any conclusions from the cases of those
patients who did not enter remission;
however 2 of the patients were aged 66
and the other was a case of erythroleu-
kaemia in which the abnormal erythroid
population rapidly disappeared with the
frst course of therapy, leaving a resistant
myeloid series to emerge from a severely
hypoplastic marrow.
It is now becoming increasingly evident
that combinations of cytotoxic therapy
using adriamycin ordaunorubicin,together
with cytosine arabinoside, 6-thioguanine
or 6-mercaptopurine, with or without
prednisone, have great potential value.
Themost successful seriesrecentlyreported
(Gale and Cline, 1977; Uzuka et al., 1976;
McCredie et al., 1974; Henderson et al.,
1975) have all used a minimum of 3 drugs
from this group, and they have become
essential components around which to
plan future therapy. The 4 series referred
to, when taken with ours, produce an
average remission rate of 79%. Since
remission rates at this level have been
achieved only recently and in few centres,
experience with maintenance therapy has
been difficult to accumulate, and our
series does little to expand or improve
the results in this area. The median dura-
tion of first remission of 48 weeks is
comparable with those ofmost ofthe more
successful series, but its disappointing
brevity reflects the lack of a satisfactory
maintenance regime. Of the 7 patients in
our series who relapsed, 3 attained an
easy second remission.
A major problem in the management of
leukaemic patients continues to be infec-
tion. The prompt investigation and treat-
ment of pyrexia in these patients is
recognizedbynursing, medical and labora-
tory staff to be ofparamount importance.
The orientation necessary for a well-
drilled routine in such episodes is one of
the strong arguments for maintaining
the practice of treating such patients in
specialized centres. It would be a mistake
to interpret the recent improvement in
remission rates as an invitation for those
with little experience in this field to
"have a go" at inducing a remission. A
similar view has been expressed recently
(Jacobs, Thompson and Whittaker, 1977).
We are fortunate in having blood and
platelettransfusionsreadily available from
the Regional Blood Transfusion Centre
within the hospital grounds, and the
recent acquisition of a cell separator has
provided the added security of granulo-
cyte transfusions. Although good suppor-
tive measures are essential, we would
emphasize the value of a rapid passage
to remission as the most important single
factor in the prevention of early deaths
from infection or haemorrhage. This has
permitted a more ambitious and successful
approach to the treatment of AML in
older patients, which may produce an
improvement in the depressing outlook
in this group to follow the encouraging
results of Gale and Cline (1977) and our-
selves. Another factor which may have
contributed to the lower success rate in
some large-scale trials is the apparent lack
of flexibility in the protocols, which are
sometimes followed too literally by the
contributing physicians. We have adopted
a flexible policy of tailoring the amount
and duration of our therapy to the needs
of individual patients. This may not
provide a very easy basis on which to run
a large-scale trial but we believe it en-
courages higher remission and survival
rates. This is not a novel approach, and
adjustments in our series have been few
and small, but we think that they have
been valuable. The therapy is for the most
part well tolerated, the only unpleasant
side-effect in some patients being nausea,
which is controlled to an acceptable level
by anti-emetic therapy.
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